Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
